SCHEDULE: Whitefort Capital Adjusts Arbutus Biopharma Stake Disclosure

Whitefort Capital entities and individuals have filed a Schedule 13G, indicating a shift in their investment intent regarding Arbutus Biopharma Corporation shares.

Summary

• This filing is an amendment to a Schedule 13G for Arbutus Biopharma Corporation, dated September 4, 2026.
• It is filed by Whitefort Capital Master Fund, LP, and related entities and individuals, including Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, and Joseph Kaplan.
• The filing indicates that as of September 4, 2026, the Reporting Persons no longer hold securities of Arbutus Biopharma with the purpose or effect of changing or influencing control of the issuer.
• This represents a change from a previous Schedule 13D filing on May 9, 2024, where their investment intent had changed.
• The Reporting Persons collectively beneficially own 15,794,261 shares of Arbutus Biopharma Corporation's Common Shares, representing approximately 8.0% of the outstanding shares.
• A Joint Filing Agreement (Exhibit 99.1) is included, confirming that the Statement on Schedule 13G is filed on behalf of each of the undersigned.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership changes and a joint filing agreement, with no new financial or strategic information.

Positives

• The filing clarifies the investment intent of Whitefort Capital entities, indicating a move away from seeking to influence or control the issuer.
• The reporting of 8.0% beneficial ownership is a clear disclosure to the market.

Negatives

• The filing does not contain any new financial performance data or strategic updates for Arbutus Biopharma Corporation.
• The shift from a Schedule 13D to a Schedule 13G might imply a reduced level of active engagement or influence by Whitefort Capital, which could be interpreted negatively by some investors if they valued Whitefort's prior stance.

Risks

• The filing does not explicitly mention any new risks or changes to existing risks for Arbutus Biopharma Corporation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Arbutus Biopharma Corporation's future performance.

Management Comments

• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by passive investors who own more than 5% of a company's stock. The shift from a Schedule 13D (which implies a more active or potentially activist stance) to a Schedule 13G suggests a reduction in the reporting persons' intent to influence corporate control, which is a common occurrence as investment strategies evolve or positions are reduced.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant shareholder's (Whitefort Capital) reduced intent to influence corporate control, which may affect market perception.
• Management: The filing confirms a change in the nature of Whitefort Capital's stake, potentially reducing pressure on management from this specific entity.

Next Steps

• Continued monitoring of Arbutus Biopharma Corporation's filings for any further changes in beneficial ownership or strategic disclosures from Whitefort Capital or other significant shareholders.

Key Dates

Keywords

Arbutus Biopharma, Whitefort Capital, Schedule 13G, Beneficial Ownership, Investment Intent, Securities Exchange Act, Shareholder Disclosure